https://scholars.lib.ntu.edu.tw/handle/123456789/517228
標題: | Comparison of hypoplastic myelodysplastic syndrome (MDS) with normo-/hypercellular MDS by International Prognostic Scoring System, cytogenetic and genetic studies | 作者: | TAI-CHUNG HUANG BOR-SHENG KO JIH-LUH TANG CHIUN HSU Chen, Chien-Yuan WOEI TSAY SHANG-YI HUANG MING YAO YAO-CHANG CHEN MING-CHING SHEN Wang C.-H. HWEI-FANG TIEN |
公開日期: | 2008 | 出版社: | Nature Publishing Group | 卷: | 22 | 期: | 3 | 起(迄)頁: | 544-550 | 來源出版物: | Leukemia | 摘要: | The differences in clinical features and prognosis between hypoplastic myelodysplastic syndrome (h-MDS) and normo-/hypercellular MDS (NH-MDS) remain unsettled. In this study, the characteristics of 37 h-MDS patients and 152 NH-MDS patients were compared. Peripheral-blood white blood cell counts and bone marrow blast percentage were lower in h-MDS patients than in NH-MDS patients (P=0.012 and 0.016, respectively). Refractory anemia (RA) was predominant (56.8%) in h-MDS, whereas RA with excess of blast (RAEB) was most common (44.7%) in NH-MDS. Chromosomal abnormalities -7/7q- occurred less frequently in h-MDS patients than in NH-MDS patients (0 vs 18.3%, P=0.022). There was no significant difference in the prevalence of mutations of RAS, AML1, JAK2, PTPN11, FLT3/ITD, and hypermethylation of SOCS1 and SHP1 between these two groups. International Prognostic Scoring System (IPSS) was ideal for predicting prognoses in h-MDS patients (P=0.002). In low- or intermediate-1 (Int-1)-risk MDS patients, h-MDS patients had a superior survival than NH-MDS patients (P=0.01). In conclusion, distinct from NH-MDS, h-MDS patients have different patterns of hemogram, distribution of French-American-British subtypes, cytogenetic changes and prognoses. IPSS is applicable in h-MDS as in NH-MDS. In patients with low- or Int-1-risk MDS, h-MDS patients have a better prognosis than NH-MDS patients. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-40749160472&doi=10.1038%2fsj.leu.2405076&partnerID=40&md5=cdd1446ef0c4513d45e40dc1e9fdd4b7 https://scholars.lib.ntu.edu.tw/handle/123456789/517228 |
ISSN: | 0887-6924 | DOI: | 10.1038/sj.leu.2405076 | SDG/關鍵字: | anthracycline derivative; antineoplastic agent; CD135 antigen; cytarabine; Janus kinase 2; protein tyrosine phosphatase; protein tyrosine phosphatase SHP 1; Ras protein; suppressor of cytokine signaling 1; transcription factor RUNX1; acute granulocytic leukemia; adolescent; adult; aged; allogeneic hematopoietic stem cell transplantation; article; child; chromosome 7; chromosome 7q; chromosome aberration; clinical feature; controlled study; diagnostic value; differential diagnosis; disease classification; female; gene mutation; high risk patient; human; human tissue; infant; International Prognostic Scoring System; leukocyte count; low drug dose; major clinical study; male; myelodysplastic syndrome; prediction; priority journal; prognosis; refractory anemia; refractory anemia with excess blasts; statistical significance; survival rate |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。